Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Cancer
AI model reveals kidney tumor features, potential for treatment response prediction
Researchers at the Dana-Farber Cancer Institute have trained artificial intelligence (AI) models to assess the clinical features of kidney cancer tumor samples to predict how tumors may respond to immune therapy.
September 22, 2023
Consumer genetic testing may misrepresent breast cancer risk: Study
Women are being told they are at high risk of breast cancer from consumer genetic test results which do not take family history into account, say researchers.
September 21, 2023
Researchers develop signature for scoring thyroid cancers
A team led by researchers at Vanderbilt University Medical Center has developed a signature for thyroid cancer aggressiveness that incorporates immune and other microenvironment features through multiomic analyses.
September 20, 2023
Myriad Genetics, Memorial Sloan Kettering collaborate on MRD testing for breast cancer
Myriad Genetics is collaborating with Memorial Sloan Kettering Cancer Center to study the use of Myriad's minimal residual disease testing platform in predicting breast cancer treatment response.
September 18, 2023
Ibex Medical Analytics launches AI-powered breast cancer biomarker scoring platform
Ibex Medical Analytics has launched a breast cancer biomarker scoring tool powered by artificial intelligence (AI) to help clinicians with treatment decisions.
September 11, 2023
Cell-penetrating peptide selectively kills melanoma cells in study
Scientists have voiced fresh hopes for metastatic skin cancer therapy after identifying a way to kill melanoma cells efficiently and selectively while sparing normal cells, according to a recent study.
September 8, 2023
Guardant 360 CDx receives approval in Japan for NSCLC
The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved the Guardant360 CDx liquid biopsy test as a companion diagnostic for select patients with HER2-mutant NSCLC who are eligible for treatment with the antibody drug conjugate Enhertu.
September 7, 2023
Roche’s Alecensa improves survival in postsurgery lung cancer patients in late-phase trial
Roche’s Alecensa has improved disease-free survival in non-small cell lung cancer patients, positioning the Swiss drugmaker to apply to expand the product label.
September 8, 2023
Oral therapy combination yields promising results in multiple myeloma study
A new agent that can be taken once daily in pill form showed promising results in a clinical trial when used in combination with a steroid in patients with multiple myeloma who had relapsed and stopped responding to currently available therapies.
September 1, 2023
Grail partners with LGBTQ+ group on study of cancer detection blood test
Grail has partnered with the Whitman-Walker Institute and the Cancer Support Community to assess the feasibility of using its multicancer early detection (MCED) Galleri blood test in a real-world setting.
September 1, 2023
Lunit to present results of AI-based immunotherapy predictive test study at WCLC 2023
Lunit announced the presentation of data from a collaborative study on the use of the Lunit SCOPE IO test to predict immunotherapy treatment outcomes in lung cancer at the 2023 World Conference on Lung Cancer (WCLC 2023).
August 28, 2023
Roche data release raises hopes TIGIT drugs can improve lung cancer survival
Roche's inadvertent release of interim data from its ongoing late-phase clinical trial has raised hopes that its anti-TIGIT immunotherapy may improve the survival rate of lung cancer patients.
August 25, 2023
Page 1 of 91
Next Page
